Related references
Note: Only part of the references are listed.Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Kai Yuan et al.
ACTA PHARMACEUTICA SINICA B (2021)
Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: LeveragingLarge-ScaleData to Inform Therapeutic Directions
Denis L. Jardim et al.
ONCOLOGIST (2021)
Chemotherapy and CDK4/6 Inhibition in Cancer Treatment: Timing Is Everything
Anne Fassl et al.
CANCER CELL (2020)
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
Martee L. Hensley et al.
CLINICAL CANCER RESEARCH (2020)
Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss
Douglas Lin et al.
GYNECOLOGIC ONCOLOGY (2020)
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
Jordan L. Kohlmeyer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
Sujana Movva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2-Advanced Breast Cancer
Ning Xie et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Patrick J. Roberts et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6-Amplified Osteosarcoma
Margot A. Lazow et al.
JCO PRECISION ONCOLOGY (2020)
Sustained Complete Response to Palbociclib in a Refractory Pediatric Sarcoma With BCOR-CCNB3 Fusion and Germline CDKN2B Variant
Timothy F. Tramontana et al.
JCO PRECISION ONCOLOGY (2020)
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R. Ahn et al.
JCO PRECISION ONCOLOGY (2020)
Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens
Margaret A. Hay et al.
JCO PRECISION ONCOLOGY (2020)
Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment
Lingge Yang et al.
JOURNAL OF CANCER (2020)
Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor
Malgorzata A. Krawczyk et al.
CANCER BIOMARKERS (2019)
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
Zhengxiao Ouyang et al.
CELL COMMUNICATION AND SIGNALING (2019)
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde et al.
CLINICAL CANCER RESEARCH (2019)
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma
Kate Lynn J. Bill et al.
ONCOLOGIST (2019)
Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease
M. E. Weidema et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma
Julia A. Bridge et al.
MODERN PATHOLOGY (2019)
Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature
Laura Loretan et al.
BREAST CARE (2019)
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Lillian M. Guenther et al.
CLINICAL CANCER RESEARCH (2019)
BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma
Nathan D. Seligson et al.
ONCOLOGIST (2019)
Gene amplification and tumor grading in parosteal osteosarcoma
Paul Chih-Hsueh Chen et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2019)
A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis
Nam Q. Bui et al.
CLINICAL SARCOMA RESEARCH (2019)
Phase 1 study of abemaciclib in children with recurrent and refractory solid tumors including malignant brain tumors
Thomas Cash et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
Ying Niu et al.
JOURNAL OF CANCER (2019)
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra et al.
NPJ BREAST CANCER (2019)
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
Michael C. Heinrich et al.
CLINICAL SARCOMA RESEARCH (2019)
Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma
Nathan D. Seligson et al.
JAMA NETWORK OPEN (2019)
Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways
Tine Cuppens et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
Yubing Zhou et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells
Ahrum Min et al.
CANCER LETTERS (2018)
Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas
Alberto S. Pappo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Integrated genetic and epigenetic analysis of myxofibrosarcoma
Koichi Ogura et al.
NATURE COMMUNICATIONS (2018)
Ewing sarcoma
Thomas G. P. Gruenewald et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma
Albiruni Abdul Razak et al.
CANCER RESEARCH (2018)
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Anusha Sriraman et al.
CELL DEATH & DISEASE (2018)
Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma
Thanh Hung Nguyen et al.
MOLECULES (2018)
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Sunkyu Kim et al.
Oncotarget (2018)
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Francesco Schettini et al.
FRONTIERS IN ONCOLOGY (2018)
BCOR-CCNB3 Fusion Positive Sarcomas A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas
Yu-Chien Kao et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21Cip1 CDK inhibitor
D. Milewski et al.
ONCOGENE (2017)
Molecular diagnostics in the management of rhabdomyosarcoma
Michael A. Arnold et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)
Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour
Inga-Marie Schaefer et al.
HISTOPATHOLOGY (2017)
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Audrey Laroche-Clary et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest
Ashleigh M. Francis et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration
Julia A. Elvin et al.
ONCOLOGIST (2017)
Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss
Yan Gao et al.
CELLULAR ONCOLOGY (2017)
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
Roman Groisberg et al.
ONCOTARGET (2017)
Managing sarcoma: where have we come from and where are we going?
Jenna S. Bleloch et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
455PPHASE I STUDY OF LEE011 (CDK4/6 INHIBITOR) IN PATIENTS WITH MALIGNANT RHABDOID TUMORS, NEUROBLASTOMA, AND CYCLIN D–CDK4/6 PATHWAY-ACTIVATED TUMORS
B. Geoerger et al.
ANNALS OF ONCOLOGY (2017)
The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation
Andrew S. Brohl et al.
SCIENTIFIC REPORTS (2017)
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Erik S. Knudsen et al.
TRENDS IN CANCER (2017)
The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies
Javier Cortes et al.
CANCER TREATMENT REVIEWS (2017)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Alexander J. Lazar et al.
CELL (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
Targeted Exome Sequencing Profiles Genetic Alterations in Leiomyosarcoma
Narasimhan P. Agaram et al.
GENES CHROMOSOMES & CANCER (2016)
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Jeffrey R. Infante et al.
CLINICAL CANCER RESEARCH (2016)
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment
Frank M. Speetjens et al.
CURRENT OPINION IN ONCOLOGY (2016)
Comprehensive genetic analysis of a paediatric pleomorphic myxoid liposarcoma reveals near-haploidization and loss of the RB1 gene
Jakob Hofvander et al.
HISTOPATHOLOGY (2016)
Liposarcoma Multimodality Management and Future Targeted Therapies
Aimee M. Crago et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas
Alessandro De Vita et al.
ONCOTARGETS AND THERAPY (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment
Jing Li et al.
ONCOTARGET (2016)
Oncogene and therapeutic target analyses in Atypical fibroxanthomas and pleomorphic dermal sarcomas
Doris Helbig et al.
ONCOTARGET (2016)
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson et al.
JAMA ONCOLOGY (2016)
Clinically Relevant Molecular Subtypes in Leiomyosarcoma
Xiangqian Guo et al.
CLINICAL CANCER RESEARCH (2015)
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Mary E. Olanich et al.
CLINICAL CANCER RESEARCH (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
Marco Perez et al.
ONCOTARGET (2015)
EWS/FLI1 target genes and therapeutic opportunities in Ewing sarcoma
Florencia Cidre-Aranaz et al.
FRONTIERS IN ONCOLOGY (2015)
Tumoral TP53 and/or CDKN2A Alterations Are Not Reliable Prognostic Biomarkers in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Daniel M. Lerman et al.
PEDIATRIC BLOOD & CANCER (2015)
Surface osteosarcoma: Clinical features and therapeutic implications
H. Nouri et al.
JOURNAL OF BONE ONCOLOGY (2015)
Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
Mark A. Dickson
CLINICAL CANCER RESEARCH (2014)
Therapeutic Targeting of Cancers with Loss of PTEN Function
Lloye M. Dillon et al.
CURRENT DRUG TARGETS (2014)
Immunohistochemical Analysis of Expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B Is Helpful in Distinction between Myxofibrosarcoma and Myxoid Liposarcoma
Tao Wang et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2014)
Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
Gerhard Hamilton et al.
MOLECULES (2014)
Translational biology of osteosarcoma
Maya Kansara et al.
NATURE REVIEWS CANCER (2014)
Classification of Rhabdomyosarcoma and Its Molecular Basis
David M. Parham et al.
ADVANCES IN ANATOMIC PATHOLOGY (2013)
Predictors of Survival and Recurrence in Primary Leiomyosarcoma
Rebecca A. Gladdy et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
Xiang-Hua Zhang et al.
CANCER BIOLOGY & THERAPY (2013)
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Mark A. Dickson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cutaneous and Subcutaneous Pleomorphic Liposarcoma A Clinicopathologic Study of 29 Cases With Evaluation of MDM2 Gene Amplification in 26
Jerad M. Gardner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4
Xiangao Huang et al.
BLOOD (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Jeffry L. Dean et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Constant p53 Pathway Inactivation in a Large Series of Soft Tissue Sarcomas with Complex Genetics
Gaelle Perot et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Recent advances in the molecular pathogenesis of Ewing's sarcoma
E. C. Toomey et al.
ONCOGENE (2010)
Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas
Antoine Italiano et al.
CLINICAL CANCER RESEARCH (2009)
Genomic and Clinical Analyses of 2p24 and 12q13-q14 Amplification in Alveolar Rhabdomyosarcoma: A Report from the Children's Oncology Group
Frederic G. Barr et al.
GENES CHROMOSOMES & CANCER (2009)
Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro
Yvonne M. Schrage et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Genetic aberrations of gastrointestinal stromal tumors
Jilong Yang et al.
CANCER (2008)
p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome
Michael Schmieder et al.
NEOPLASIA (2008)
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
Samuel Singer et al.
CANCER RESEARCH (2007)
p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas
Manish M. Subramaniam et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Analysis of the expression of cell cycle regulators in Ewing cell lines:: EWS-FLI-1 modulates p57KIP2 and c-Myc expression
L Dauphinot et al.
ONCOGENE (2001)
Share Paper
